The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation
Open accessAbstract
The AML1 transcription factor is essential for normal hematopoiesis and is the target of several chromosomal translocations in acute leukemia. Acquired somatic AML1 mutations were recently demonstrated sporadically in de novo myelodysplasia (MDS) and acute myeloid leukemia (AML) including a few cases of therapy-related disease (t-MDS/t-AML). We examined 140 patients with t-MDS or t-AML for AML1 mutations by direct sequencing. We identified 9 missense, 3 nonsense, and 10 frameshift mutations, all heterozygous, in 22 patients (15.7%). Thirteen mutations were located in the N-terminal Runt homology domain (RHD), whereas 9 mutations were located in the C-terminal region including the transactivation domain (TAD). Nineteen patients with AML1 mutations had previously received alkylating agents whereas 2 patients had received radiotherapy only. AML1 mutations were highly significantly associated with presentation of the disease as t-MDS (P = .003), with deletion or loss of chromosome arm 7q (P = .001) and with subsequent transformation to overt t-AML (P = .0001). Patients with missense mutations presented a shorter survival compared with patients with nonsense/frameshift mutations (P = .03). Our results suggest that AML1 mutations and deletion of genes on chromosome arm 7q cooperate in leukemogenesis and predispose to leukemic transformation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Acquired monoallelic RUNX-1 mutations occur in about 15% of cases of de novo MDS, particularly those that progress to AML”
From Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. (2009) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · cited 1×
“160 15/F Non-Hodgkin lymphoblastic (II A) Ctx Dox Vcr Pred (3) HD-Mtx (1) BEAM ASCT (PB) 16 12 12 M1 14 46,XX,der(5)del(5)(p?)del(5) (q?), 5, mar[6]/46,XX, der(12)t(3;12)(p11;q11), der(16)t(16;21)46,XX[23] 165 57/F Non-Hodgkin NCB (IVB) Ctx Etop Mtx AraC Pred (6) Ctx Dox Vcr Pred (8) Ctx Vcr Pred (11) Clb (10), Ctx (3…”
Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics
Maquat, L. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1310 · Cited by 1,214
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100
Smith, S. M., Le Beau, M. M., Huo, D., Karrison, T., Sobecks, R. M., Anastasi, J., Vardiman, J. W., Rowley, J. D., & Larson, R. A. (2003) · Blood · doi:10.1182/blood-2002-11-3343 · Cited by 682
Le Beau, M. M., Albain, K. S., Larson, R. A., Vardiman, J. W., Davis, E. M., Blough, R. R., Golomb, H. M., & Rowley, J. D. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.325 · Cited by 671
Core-binding factors in haematopoiesis and leukaemia
Speck, N. A., & Gilliland, D. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc840 · Cited by 569 · cited 1×
“108 69/M Urinary bladder cancer X-ray, urinary bladder, 40 Gy 29 RAEB 2 2 45,XY, 3, 7,del(12)(p11), 16, 2mar[20]/46,XY[2] 114 50/M Hodgkin MC (IIIB) Me Vcr Pro Pred (6) 78 t-MDS 19 19 46,XX, 1,dic(1;7)(p11;q11) [16]/46,XX[12] 117 56/F Non-Hodgkin NM (IIIA) Ctx Dox Vcr Pred Bleo (7) Ctx Vcr Pred (13), Clb Vcr Pred (17)…”
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins
Ayton, P. M., & Cleary, M. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204639 · Cited by 500
Rowley, J., Golomb, H., & Vardiman, J. (1981) · Blood · doi:10.1182/blood.v58.4.759.759 · Cited by 441 · cited 1×
“16 67/F Non-Hodgkin NLWD (IIIB) Vcr Pred Stn (6) Ctx Vcr Predn (36) 48 RAEB3 t-AML 44 62 45,XX, 7[13] 46,XX[7] 38 39/M Hodgkin NS (IIIB) CVPPR (5), MOPPR (14) Bleo Dtic O PR Adm (14) Clb (17), BVPR (8) MOPPR (9) Stereocyt (19) 90 RA3M1 5 6 46,XY, 1,dic(1;7)(p11;q11) [22]/46,XY, 5,del(7)(q22), 8, 21, der(21;22) (a10;q1…”
Osato, M., Asou, N., Abdalla, E., Hoshino, K., Yamasaki, H., Okubo, T., Suzushima, H., Takatsuki, K., Kanno, T., Shigesada, K., et al. (1999) · Blood · doi:10.1182/blood.v93.6.1817.406k36_1817_1824 · Cited by 397
Michaud, J. (2002) · Blood · doi:10.1182/blood.v99.4.1364 · Cited by 367 · cited 1×
“108 69/M Urinary bladder cancer X-ray, urinary bladder, 40 Gy 29 RAEB 2 2 45,XY, 3, 7,del(12)(p11), 16, 2mar[20]/46,XY[2] 114 50/M Hodgkin MC (IIIB) Me Vcr Pro Pred (6) 78 t-MDS 19 19 46,XX, 1,dic(1;7)(p11;q11) [16]/46,XX[12] 117 56/F Non-Hodgkin NM (IIIA) Ctx Dox Vcr Pred Bleo (7) Ctx Vcr Pred (13), Clb Vcr Pred (17)…”
Cited by
Haferlach, T., Kohlmann, A., Wieczorek, L., Basso, G., Kronnie, G. T., Béné, M.-C., De Vos, J., Hernández, J. M., Hofmann, W.-K., Mills, K. I., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4732 · Cited by 654
Role of RUNX1 in hematological malignancies
Sood, R., Kamikubo, Y., & Liu, P. (2017) · Blood · doi:10.1182/blood-2016-10-687830 · Cited by 494
The runx genes: gain or loss of function in cancer
Blyth, K., Cameron, E. R., & Neil, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1607 · Cited by 455
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
Bejar, R., Levine, R., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 305
Metadata
- Authors
- Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J.
- Affiliations
- Rigshospitalet (DK)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-09-01
- Volume
- 104
- Issue
- 5
- Pages
- 1474-1481
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2154725061
- Cited by
- 135
- References
- 38
- Citations by year
- 2025: 1 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 8 · 2019: 4 · 2018: 2 · 2017: 9 · 2016: 6 · 2015: 3 · 2014: 6 · 2013: 10 · 2012: 5
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kræftens Bekæmpelse
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- therapy-related myelodysplastic syndrome, therapy-related acute myeloid leukemia, alkylating agents, chromosome 7q deletion, leukemic transformation, transactivation domain, somatic mutations, leukemogenesis, survival
- MeSH terms
- Acute Disease, Adult, Aged, Cell Transformation, Neoplastic, Chromosome Deletion, Chromosomes, Human, Pair 7, DNA-Binding Proteins, Female, Humans, Leukemia, Myeloid, Male, Middle Aged, Proto-Oncogene Proteins, Transcription Factors, Frameshift Mutation, In Situ Hybridization, Fluorescence, Codon, Nonsense, Antineoplastic Agents, Alkylating, Loss of Heterozygosity, Mutation, Missense, Polymorphism, Single Nucleotide, Core Binding Factor Alpha 2 Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. https://app.cochat.ai/papers/10.1182/blood-2004-02-0754
- The paper
- Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2004). Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. https://doi.org/10.1182/blood-2004-02-0754
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.